Medicare Advantage is on the hot seat. High-profile critics like Don Berwick and Richard Gilfillan have called it the “Money Machine” in the pages of Health Affairs because of profit it has delivered to health system stakeholders. Congressional inquiries have…
Author: Rick Ankrum
Rare Diseases May Be Unprofitable to Treat, but That Doesn’t Mean Government Intervention Will Help
What is an orphan drug? It is one that will address a disease that negatively impacts only a few people. Why is the orphan drug perennially in the news? This is because it can be and is used to constitute…